DexCom’s CGM in Type 2 diabetes shows benefits

DexCom will showcase its focus on Dexcom CGM use among people with Type 2 diabetes and the launch of the Omnipod 5 Automated Insulin Delivery System with Dexcom G7 at the 84th Scientific Sessions of the American Diabetes Association conference held June 21-24 in Orlando. This data shows clinically meaningful decreases in A1C and increases in time in range for Dexcom CGM users with Type 2 diabetes both on insulin and not on insulin. Additionally, studies presented at the conference demonstrate Dexcom CGM use by people with Type 2 diabetes not on insulin is associated with improved A1C independent of anti-diabetes medication, and there may be further benefits of CGM for this population when used in combination with therapies such as GLP-1s. Another study presented at ADA demonstrates Dexcom CGM is a behavior modification tool for people with prediabetes. In this study, Dexcom CGM use was associated with improved self-reported psychosocial health and self-care behaviors in participants with prediabetes including perceived benefits related to eating, physical activity, weight, blood pressure, worry, energy levels and healthcare provider interactions.